Janux Therapeutics Inc — Stato Patrimoniale (NASDAQ:JANX) | MetaTrader

Apri il grafico completo

Financials

Panoramica Estratto Conto Statistiche

Trimestrale Annuale

Totale attivo 379.82 M364.01 M380.41 M1.06 B1 B Totale passività 13.5 M43.27 M36.06 M38.73 M44.74 M Patrimonio netto totale 366.33 M320.74 M344.35 M1.02 B956.82 M Totale passività e patrimonio netto 379.82 M364.01 M380.41 M1.06 B1 B Debito totale ————— Indebitamento netto —————

Notizie

Truist taglia il target di prezzo di Janux Therapeutics per la concorrenza

Truist cuts Janux Therapeutics stock price target on competition

Janux therapeutics doses first participant in JANX011 phase 1 trial

Vir Biotechnology Stock: The Low-Down On The Readouts Ahead (NASDAQ:VIR)

Wall Street Analysts See a 319.23% Upside in Janux Therapeutics (JANX): Can the Stock Really Move This High?

Janux Therapeutics nomina William Go come nuovo direttore medico

Janux Therapeutics appoints William Go as new chief medical officer

Bristol-Myers Squibb: Solid Tumor Collaboration With Janux And Camzyos Expansion (BMY)

JANX Enters Global Oncology Collaboration With BMY, Stock Rises

Il titolo Janux sale dopo l’accordo di collaborazione con Bristol Myers Squibb

Janux stock rises after Bristol Myers Squibb collaboration deal

Janux Therapeutics Strikes Bristol Myers Biotech Deal Worth $800 Million - Janux Therapeutics (NASDAQ:JANX)